11 February 2026
11 February 2026
Callavid is a medical device designed to offer leak-resistant administration of vaginal medications.
The trial enrolled 99 patients across 15 sites in the US.
Under the agreement, Insilico Medicine will receive R&D funding for each programme.
The total number of patients enrolled across both parts is anticipated to exceed 650.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
